There is little doubt that the clinical management of cancer has enjoyed significant
improvements in the past decade, brought about by consolidating the skills and experience …

Glioblastoma is one of the most aggressive central nervous system malignancies with high
morbidity and mortality. Current clinical approaches, including surgical resection …

Doxorubicin (DOX) is widely used as a chemotherapeutic agent for both hematologic and
solid tumors and is a reasonable candidate for glioma treatment. However, its effectiveness …

Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma
multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment. Both …

Brain cancer persists as a difficult‐to‐treat condition. In particular, metastatic brain cancer
and malignant primary brain tumors such as glioblastoma (GBM) are among the most deadly …

Cancer continues to be a prevalent and lethal disease, despite advances in tumor biology
research and chemotherapy development. Major obstacles in cancer treatment arise from …

Simple Summary The advancement of nanotechnology over the last three decades has
given new hope to cancer management. The first FDA-approved nanomedicine (DOXIL) was …

Simple Summary Glioblastoma multiforme (GBM) are among the most lethal tumors. The
highly invasive nature and presence of GBM stem cells, as well as the blood brain barrier …

Nanomedicine is a rapidly growing field that uses nanomaterials for the diagnosis, treatment
and prevention of various diseases, including cancer. Various biocompatible nanoplatforms …

Background Glioblastoma multiforme (GBM) is a fatal malignant primary brain tumor in
adults. The therapeutic efficacy of chemotherapeutic drugs is limited due to the blood-brain …